Francesca CONRADIE to Microbial Sensitivity Tests
This is a "connection" page, showing publications Francesca CONRADIE has written about Microbial Sensitivity Tests.
Connection Strength
0,246
-
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 04; 23(4):e122-e137.
Score: 0,049
-
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022 04; 22(4):496-506.
Score: 0,045
-
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022 02; 22(2):242-249.
Score: 0,044
-
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020 03; 55(3).
Score: 0,040
-
Frequency of Circulating CD4+Ki67+HLA-DR- T Regulatory Cells Prior to Treatment for Multidrug Resistant Tuberculosis Can Differentiate the Severity of Disease and Predict Time to Culture Conversion. Front Immunol. 2018; 9:2438.
Score: 0,036
-
A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis. PLoS One. 2017; 12(5):e0176660.
Score: 0,033